Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05386888 Org: User:
Start: 09/09/22 End: 07/31/25 Due: 07/31/26

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase: N/A Priority: Normal
NCT ID: NCT05934513 Org: User:
Start: 09/06/23 End: 06/30/26 Due: 06/30/27

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04914286 Org: User:
Start: 10/20/21 End: 12/31/23 Due: 12/31/24

A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT06898255 Org: User:
Start: 04/24/25 End: 07/06/26 Due: 07/06/27

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06500676 Org: User:
Start: 07/09/24 End: 12/31/28 Due: 12/31/29

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07026916 Org: User:
Start: 08/01/25 End: 08/01/28 Due: 08/01/29

A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05756153 Org: User:
Start: 04/25/23 End: 08/31/25 Due: 08/31/26

A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT06375733 Org: User:
Start: 03/20/24 End: 12/31/26 Due: 12/31/27